Tenax Therapeutics Engages in Important Conference
CHAPEL HILL, N.C. — Tenax Therapeutics, Inc. (NASDAQ: TENX), a pharmaceutical company in Phase 3 of development, focuses on innovating solutions for cardiovascular and pulmonary diseases. They recently announced participation in a prominent healthcare event in Boston, an opportunity for them to highlight their ongoing research and advancements.
Key Details of the Conference Participation
The Guggenheim Healthcare Innovation Conference is set to occur soon, allowing Tenax to showcase its progress and insights. Chris Giordano, the company’s CEO, will deliver a presentation focusing on the company’s trajectory and the specifics of levosimendan's development.
Presentation Format and Schedule
Giordano will be part of a fireside chat session where he will discuss the company's vision and future plans. Mark your calendars for November 13, when he will present at 1:00 PM EST. Investors can tune in live or catch the recorded session afterward.
About Levosimendan and Its Importance
Levosimendan plays a critical role in treating conditions that significantly affect cardiovascular health. Tenax holds the global rights to develop not only IV formulations but also subcutaneous and oral versions, promising a diverse approach to treatment. This flexibility can significantly impact patient care and outcomes in a field where options have been limited.
Additional Innovations in Development
In addition to levosimendan, Tenax is also working on a unique oral formulation of imatinib. This effort reflects the company’s ongoing commitment to addressing high unmet medical needs in the pharmaceutical landscape, demonstrating their innovative spirit and responsiveness to patient requirements.
Tenax Therapeutics' Vision
Founded with a mission to transform treatment landscapes for severe conditions, Tenax Therapeutics focuses on rigorous development and comprehensive patient care. By emphasizing research that meets critical healthcare needs, they are well-positioned to influence the future of treatment in their target areas.
Contact Information for Investor Relations
For individuals looking to connect with the company, Tenax encourages inquiries through its investor contacts. John Fraunces, Managing Director at LifeSci Advisors, can be reached at 917-355-2395. Brian Mullen, also affiliated with LifeSci Advisors, is available at 203-461-1175.
Frequently Asked Questions
What is the focus of Tenax Therapeutics?
Tenax Therapeutics concentrates on developing products for cardiovascular and pulmonary diseases, addressing significant unmet medical needs.
Who will be presenting at the conference?
Chris Giordano, the CEO of Tenax Therapeutics, will present at the Guggenheim Healthcare Innovation Conference.
When is the Guggenheim Healthcare Innovation Conference?
The conference is scheduled from November 11 to 13, with Tenax's presentation on November 13 at 1:00 PM EST.
What is levosimendan?
Levosimendan is a drug that enhances cardiac function and is central to Tenax's research efforts aimed at treating heart-related conditions.
How can investors get more information about Tenax's activities?
Investors can reach out to Tenax Therapeutics through their dedicated investor contacts for the latest updates and information.
